Serum exosomal miRNA contributes to the diagnosis of leptomeningeal carcinomatosis
Quick Facts
- Publication title: Serum exosomal miRNA contributes to the diagnosis of leptomeningeal carcinomatosis
- Journal: J Neurooncol
- Year: 2025
- DOI: 10.1007/s11060-025-04999-x
- PMID/PMCID: 40080246; PMC12106567
Research overview
In this study, serum samples were collected from lung adenocarcinoma patients with LC. And the combination of miRNA-1296-5p, miR-499a-5p and miR-370-3p with CEA can further enhance this potential.
Key findings
The results of miRNA sequencing revealed seven differentially enriched miRNAs (miRNA-1296-5p, miR-503-5p, miR-499a-5p, miR-374a-5p, miR-3173-5p, miR-370-3p and miR-885-3p).
0001), displaying higher diagnostic power for LC.
Study design
In this study, serum samples were collected from lung adenocarcinoma patients with LC.
The control groups consisted of patients with early-stage and advanced-stage lung adenocarcinoma without LC.
Serum exosomes were isolated for high - throughput RNA sequencing to screen for differential miRNAs, and the results were validated in 123 samples.
Echo Biotech Role
Echo Biotech contributed EV isolation and purification, EV characterization, miRNA profiling/sequencing and bioinformatic analysis; the study also used or cited Exosupur®.
Related platforms: Exoomics®, Research Reagents & Tools
Related services and capabilities: Biofluid EV Isolation & Purification, EV Basic Characterization (TEM/NTA/WB), EV miRNA Profiling / Sequencing, Research Reagent / Product Supply
Related products or reagents: Exosupur® EV Isolation/Purification Kit
References
Original publication: Serum exosomal miRNA contributes to the diagnosis of leptomeningeal carcinomatosis Journal of neuro-oncology. 2025. DOI: 10.1007/s11060-025-04999-x. PMID/PMCID: 40080246; PMC12106567.